Phase I Clinical Trial
Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy
... a clinical trial (NCT02318771). The trial schema is illustrated in ...The trial enrolls patients with metastatic lung cancer, melanoma, head and neck cancer, or ...
7
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
... by Clinical Laboratory Improvement Amendment (CLIA) certified mutational analysis including isolation of genomic DNA from the tumor; polymerase chain reaction (PCR) amplification of exons 8, 9, 11, 13, and 17 of ...
10
Phase I clinical trial of HER2 specific immunotherapy with concomitant HER2 kinase inhibtion
... while others, such as sunitinib, have had no detrimental effects or potentially improve immune responses [19,20]. We observed potent antibody responses to HER2 ECD and ICD, suggesting that we could still break tolerance ...
9
A Bayesian approach for dose escalation in a phase I clinical trial incorporating pharmacodynamic endpoints
... Bayesian decision procedures have already been proposed for and implemented in phase I dose-escalation studies in healthy volunteers. The procedures have been based on pharmacokinetic responses reflecting ...
22
A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial
... Gene-based vaccine technology provides a safe avenue for producing candidate vaccines for select agents without the need for extreme biocontainment. Gene-based vectors for filo- viruses are particularly attractive ...
11
Phase I clinical trial results of aceneuramic acid for GNE myopathy in Japan
... in Trial-1 which used conventional tablets and measured total aceneuramic acid, and therefore Trial-2 was performed using and comparing the trial outcomes from ...the clinical dose for an ...
15
Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
... In summary, SIPIPI was well tolerated and resulted in cancer- specific immunoglobulin titers that increased above the pretreatment baseline with SIP-T and were further elevated after the administration of IPI. Over the ...
6
Phase I clinical trial of multiple peptide vaccination for patients with advanced biliary tract cancer
... This study was conducted as a phase I trial. Patients who received standard chemotherapy under a diagnosis of inoperable BTC between June 2009 and May 2010 were invited to participate after providing ...
11
Effect of Electromagnetic Form of Melilotus Officinalis Extract on Dermal Wound Healing in Diabetic Mice
... 13. Heshmat R, Mohammad K, Mohajeri Tehrani MR, Tabatabaie Malazy O, Keshtkar AA, Gharibdoust F, Larijani B. Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARSTM) in patients with diabetic foot ...
9
Replication selective adenoviruses as oncolytic agents
... Optimizing tumor-selective adenovirus replication Two broad approaches are currently being used to engi- neer tumor-selective adenovirus replication (Figure 2). The first is to limit the expression of the E1A gene ...
6
Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses
... This clinical study entitled UL-CMV-1 (EudraCT ...this phase I clinical trial was to test the safety and feasibility of this peptide ...
14
Emerging therapeutic potential of nanoparticles in pancreatic cancer: a systematic review of clinical trials
... restrictions. Clinical trials involving the use of nanoparticles as a therapeutic or prognostic option in patients with pancreatic cancer were ...10 clinical trials including one randomised control ...
20
Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor
... another clinical trial entitled “A phase I/II trial of boron neutron capture therapy combined with image‑guided intensity‑modulated radiotherapy (IG‑IMRT) for locally recurrent HN ...
7
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial
... In Phase III, GBM-only patients will be randomized to receive either 60 GyE (2 GyE per fraction) of proton irradia- tion with concurrent TMZ (control arm) or a CIRT boost (dose determined in Phase I ...
12
Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma
... being unique to each neoplastic B cell clone. However, provoking sufficient immunogenicity of the Id, which represents a tumor-specific antigen [2], but nevertheless is a self-protein, is a still unmet challenge. ...
11
Validating intramyocardial bone marrow stem cell therapy in combination with coronary artery bypass grafting, the PERFECT Phase III randomized multicenter trial: study protocol for a randomized controlled trial
... PERFECT trial, representing the first Phase III trial for evaluation of intramyocardial bone marrow stem cell therapy during CABG surgery, was initiated in ...and clinical results from ...
5
Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042
... We analyzed the local immune infiltrates in injected lesions obtained from advanced primary CTCL and multi- lesional CBCL patients enrolled in the Phase I and II steps of a clinical trial ...
11
<p>Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date</p>
... in Phase I/II clinical trials, a Phase III clinical trial that evaluated the role of pembroli- zumab (KEYNOTE-240) in advanced HCC patients who had prior exposure to sorafenib in ...
8
Cancer-associated antigens and their clinical potential for immunotherapy
... protein. Phase I and II clinical trial of 5T4 vaccine in renal [41], colorectal [42] and resistant prostate cancer [43] showed increased clinical ...
11
Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report
... after trial completion could be disclosed to the vaccine trial unit, contingent on the subject’s ...the Phase Ia/Ib clinical trial was confirmed as safety and a minimal 60 % ...
11